|Bid||64.00 x 203800|
|Ask||66.00 x 10000|
|Day's range||59.24 - 60.37|
|52-week range||54.84 - 79.05|
|PE ratio (TTM)||17.16|
|Earnings date||20 Oct 2017|
|Dividend & yield||0.00 (0.00%)|
|1y target est||65.80|
-- New indication comes just 18 months after launch of BRIVIACT® in the U.S. This is a new indication for BRIVIACT, which is already approved in the U.S. as adjunctive treatment for POS in patients in this age group.
Presentations included the first 48- week data from the CIMPASI-1 and CIMPASI-2 psoriasis trials, and re-randomized data through 48 weeks from the CIMPACT psoriasis trial 1,2 Treatment with CIMZIA was ...
THOUSAND OAKS, Calif. and BRUSSELS, Sept. 11, 2017 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced detailed results from the Phase 3 ARCH study showing that 12 months of EVENITY™* (romosozumab) followed by alendronate was superior in reducing new vertebral, clinical, non-vertebral and hip fracture risk in postmenopausal women with osteoporosis at high risk for fracture, compared to alendronate alone. Overall adverse events and serious adverse events were generally similar between the treatment groups with the exception of the previously reported imbalance in positively adjudicated cardiovascular serious adverse events.